Drug Information

Drug General Information
Drug ID
D02ZHW
Former ID
DIB016950
Drug Name
177Lu-DOTA-octreotate (neuroendocrine tumors), Advanced Accelerator Applications
Synonyms
Lutate; Lutathera; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate
Indication Melanoma [ICD9: 172; ICD10:C43] Phase 3 [523870]
Company
Advanced accelerator applications
Structure
Download
2D MOL

3D MOL
Canonical SMILES
N([C@H](C(=O)O)[C@H](O)C)C(=O)[C@@H]1CSSC[C@H](NC(=O)[C<br />@H](NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)Cc<br />2ccccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]<br />(C(=O)N1)[C@H](O)C)CCCCN)Cc1c[nH]c2c1cccc2)Cc1ccc(cc1)O<br />.[177Lu+3]
Target and Pathway
Target(s) Somatostatin receptor Target Info Modulator [532708]
References
Ref 523870ClinicalTrials.gov (NCT01578239) A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours. U.S. National Institutes of Health.
Ref 532708Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.